Evidence map›Paper›PMID 42856846›Full record

ArticleFrontiers in oncology2026

Phenotypic, functional and metabolic features of B cells from a small cohort of breast cancer patients.

Kate Miller, Andrew Gelsomini, Maria Romero, Denisse Garcia, Alain Diaz, Valquiria Bueno, Jenna Hansen, Roland Jurecic, Michael H Antoni, Daniela Frasca

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kate Miller *Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, United States.
Andrew Gelsomini *Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, United States.
Maria Romero *Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, United States.
Denisse GarciaDepartment of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, United States.
Alain DiazDepartment of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, United States.
Valquiria BuenoDepartment of Microbiology, Immunology and Parasitology, Federal University of São Paulo, São Paulo, Brazil.
Jenna HansenDepartment of Psychology, University of Miami, Coral Gables, FL, United States.
Roland JurecicDepartment of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, United States.
Michael H AntoniDepartment of Psychology, University of Miami, Coral Gables, FL, United States.
Daniela FrascaDepartment of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, United States.

Funding

Tumor Biology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI George S. Grills · 2019 to 2026
$24.1M
(PQ9) Characterization and prophylactic treatment of chemotherapy-induced long-term adverse sequelaeR01CA208634 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI JURECIC, ROLAND · 2016 to 2020
$2.8M
Obesity accelerates age defects in human B cells and induces autoimmunityR56AG059719 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI FRASCA, DANIELA · 2018 to 2018
$384k
NCI NIH HHS P30 CA240139NCI NIH HHS R01 CA208634NIA NIH HHS R56 AG059719
6 · The paper itself

Abstract

Objective: Identify and characterize breast cancer (BC)-induced changes of humoral immunity and B cell function in a small cohort of treatment-naïve breast cancer patients (BCPs) as compared to healthy controls (HCs). Methods: The peripheral blood from newly diagnosed, treatment-naive breast cancer patients (BCPs) and age-matched cancer-free individuals (HCs) was collected. B cells were isolated and cellular, molecular, functional and metabolic analyses were performed. Results: There is a redistribution of B cell subsets in the blood of BCPs versus HCs with increased frequencies of pro-inflammatory B cell subsets in BCPs. B cells from BCPs secrete higher amounts of pro-inflammatory cytokines than B cells from HCs, due to the activation of the transcription factor NF-kB. B cells from BCPs also secrete high amounts of the metabolite lactate and are highly glycolytic, as shown in a Seahorse mitostress test. This hyper-metabolic phenotype can be inhibited at least Conclusion: Results have identified a set of distinct and significant changes in the circulating B cells of our cohort of BCPs that may help to establish a baseline B cell signature of BCPs before therapy, to predict B cell performance during therapy by identifying immunosuppressive cells, and to design precision therapeutic approaches.

Indexed as

B cellsbreast cancerinflammationlactatemetabolism

Identifiers

PMID42856846
PMCPMC13649394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.